Updated Licence For Goserelin (Zoladex 3.6 Mg & Zoladex La 10.8mg) Reflects Survival Benefits In All Stages Of Prostate Cancer

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated licence to goserelin 3.6mg and goserelin LA 10.8mg [i] to reflect survival benefits in all three stages of prostate cancer (localised, locally advanced and advanced also called metastatic).